{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:46:03Z","timestamp":1762508763065,"version":"3.40.5"},"reference-count":115,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,1]]},"abstract":"<jats:p>Pediatric autoimmune bullous disease is a rare group of blistering skin disorders in children that result from autoimmunity against intercellular and basement membrane antigens in the skin and mucous membranes. Most pediatric cases are treated with oral corticosteroids or longer-term immunosuppressants such as azathioprine or mycophenolate mofetil. Immunomodulating drugs such as rituximab are increasingly being considered as options for refractory disease.<\/jats:p>","DOI":"10.1542\/pir.2021-005125","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T03:03:37Z","timestamp":1654052617000},"page":"309-321","source":"Crossref","is-referenced-by-count":1,"title":["Pediatric Autoimmune Bullous Disease: A Literature Review and Update on Management"],"prefix":"10.1542","volume":"43","author":[{"given":"Rosalind","family":"Ashton","sequence":"first","affiliation":[{"name":"*University of Ottawa, Ottawa, ON, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiva","family":"Fassihi","sequence":"additional","affiliation":[{"name":"\u2020St John\u2019s Institute of Dermatology, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, England"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2022,6,1]]},"reference":[{"issue":"13","key":"2022060103033136000_B1","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1177\/0961203314544187","article-title":"Childhood-onset bullous systemic lupus erythematosus","volume":"23","author":"Louren\u00e7o","year":"2014","journal-title":"Lupus"},{"issue":"3","key":"2022060103033136000_B2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/pde.12025","article-title":"Extragenital bullous lichen sclerosus in a pediatric patient: a case report and literature review","volume":"31","author":"Shiver","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2022060103033136000_B3","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/pde.12214","article-title":"Childhood lichen planus pemphigoides: report of two cases treated successfully with systemic glucocorticoids and dapsone","volume":"31","author":"Goldscheider","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2022060103033136000_B4","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2310\/7750.2011.10040","article-title":"Bullous scabies simulating pemphigoid","volume":"15","author":"Roxana Stan","year":"2011","journal-title":"J Cutan Med Surg"},{"issue":"11","key":"2022060103033136000_B5","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s11882-017-0748-4","article-title":"Mastocytosis in children","volume":"17","author":"Klaiber","year":"2017","journal-title":"Curr Allergy Asthma Rep"},{"issue":"421","key":"2022060103033136000_B6","first-page":"507","article-title":"Chronic bullous disease of childhood: another cause for potential misdiagnosis of sexual abuse?","volume":"47","author":"Coleman","year":"1997","journal-title":"Br J Gen Pract"},{"issue":"1","key":"2022060103033136000_B7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.clindermatol.2011.03.018","article-title":"Autoimmune bullous diseases in childhood","volume":"30","author":"Sansaricq","year":"2012","journal-title":"Clin Dermatol"},{"issue":"4843","key":"2022060103033136000_B8","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1126\/science.2894075","article-title":"A newly characterized HLA DQ beta allele associated with pemphigus vulgaris","volume":"239","author":"Sinha","year":"1988","journal-title":"Science"},{"issue":"2","key":"2022060103033136000_B9","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40257-017-0257-1","article-title":"The inpatient burden of autoimmune blistering disease in US children: analysis of nationwide inpatient sample data","volume":"18","author":"Ren","year":"2017","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"2022060103033136000_B10","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1046\/j.1365-4362.1999.00764.x","article-title":"Childhood, neonatal, and stillborn pemphigus vulgaris","volume":"38","author":"Bjarnason","year":"1999","journal-title":"Int J Dermatol"},{"issue":"1","key":"2022060103033136000_B11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00418-008-0420-0","article-title":"The desmosome and pemphigus","volume":"130","author":"Waschke","year":"2008","journal-title":"Histochem Cell Biol"},{"issue":"5","key":"2022060103033136000_B12","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1111\/bjd.15930","article-title":"British Association of Dermatologists\u2019 guidelines for the management of pemphigus vulgaris 2017","volume":"177","author":"Harman","year":"2017","journal-title":"Br J Dermatol"},{"issue":"5","key":"2022060103033136000_B13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1525-1470.2011.01514.x","article-title":"Analysis of current therapy and clinical outcome in childhood pemphigus vulgaris","volume":"28","author":"Mabrouk","year":"2011","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2022060103033136000_B14","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/0030-4220(94)90322-0","article-title":"Pemphigus vulgaris in adolescence: a case presentation and review of the literature","volume":"77","author":"Gorsky","year":"1994","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"3","key":"2022060103033136000_B15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.det.2011.03.012","article-title":"Diagnosis and clinical features of pemphigus foliaceus","volume":"29","author":"James","year":"2011","journal-title":"Dermatol Clin"},{"key":"2022060103033136000_B16","first-page":"299","article-title":"Pemphigus and environmental factors","volume":"138","author":"Ruocco","year":"2003","journal-title":"G Ital Dermatol Venereol"},{"issue":"1","key":"2022060103033136000_B17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/archderm.1993.01680220081019","article-title":"Pemphigus foliaceus in young women: an endemic focus in the Sousse area of Tunisia","volume":"129","author":"Morini","year":"1993","journal-title":"Arch Dermatol"},{"issue":"6","key":"2022060103033136000_B18","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1365-2133.1988.tb02590.x","article-title":"South American pemphigus foliaceus: study of an epidemic in El Bagre and Nechi, Colombia 1982 to 1986","volume":"118","author":"Robledo","year":"1988","journal-title":"Br J Dermatol"},{"issue":"1","key":"2022060103033136000_B19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1087-0024.2004.00833.x","article-title":"Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem)","volume":"9","author":"Aoki","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"4","key":"2022060103033136000_B20","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.clindermatol.2011.01.013","article-title":"Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis)","volume":"29","author":"Joly","year":"2011","journal-title":"Clin Dermatol"},{"issue":"1","key":"2022060103033136000_B21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/1346-8138.12675","article-title":"Update on fogo selvagem, an endemic form of pemphigus foliaceus","volume":"42","author":"Aoki","year":"2015","journal-title":"J Dermatol"},{"issue":"1","key":"2022060103033136000_B22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1399-0039.1997.tb02707.x","article-title":"An epitope in the third hypervariable region of the DRB1 gene is involved in the susceptibility to endemic pemphigus foliaceus (fogo selvagem) in three different Brazilian populations","volume":"49","author":"Moraes","year":"1997","journal-title":"Tissue Antigens"},{"issue":"6","key":"2022060103033136000_B23","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.clindermatol.2015.09.007","article-title":"Bullous diseases: kids are not just little people","volume":"33","author":"Marathe","year":"2015","journal-title":"Clin Dermatol"},{"issue":"5","key":"2022060103033136000_B24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0190-9622(96)90729-X","article-title":"Penicillamine-induced bullous dermatoses","volume":"35","author":"Bialy-Golan","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2022060103033136000_B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000051673","article-title":"Severe childhood pemphigus vulgaris aggravated by enalapril","volume":"202","author":"Thami","year":"2001","journal-title":"Dermatology"},{"issue":"4","key":"2022060103033136000_B26","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.clindermatol.2013.01.004","article-title":"Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies","volume":"31","author":"Ruocco","year":"2013","journal-title":"Clin Dermatol"},{"issue":"1","key":"2022060103033136000_B27","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/11310380-000000000-00000","article-title":"A current review of juvenile pemphigus vulgaris: analysis of data on clinical outcomes","volume":"11","author":"Asarch","year":"2010","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"2022060103033136000_B28","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1111\/j.1440-0960.2010.00661.x","article-title":"Pemphigus vulgaris in three adolescents: the course of the disease","volume":"52","author":"Popadic","year":"2011","journal-title":"Australas J Dermatol"},{"issue":"5","key":"2022060103033136000_B29","doi-asserted-by":"crossref","first-page":"1062.e1","DOI":"10.1016\/j.jpeds.2014.07.023","article-title":"Pemphigus foliaceus in an adolescent","volume":"165","author":"Adah","year":"2014","journal-title":"J Pediatr"},{"issue":"2","key":"2022060103033136000_B30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1525-1470.2012.01730.x","article-title":"Pediatric pemphigus vulgaris: durable treatment responses achieved with prednisone and mycophenolate mofetil (MMF)","volume":"30","author":"Baratta","year":"2013","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2022060103033136000_B31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1525-1470.2008.00808.x","article-title":"Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulin therapy","volume":"26","author":"Asarch","year":"2009","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2022060103033136000_B32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2022060103033136000_B33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12016-007-8021-6","article-title":"Rituximab in treatment-resistant autoimmune blistering skin disorders","volume":"34","author":"Schmidt","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"2022060103033136000_B34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"issue":"10083","key":"2022060103033136000_B35","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"389","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"10083","key":"2022060103033136000_B36","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/S0140-6736(17)30787-0","article-title":"Rituximab as first-line treatment of pemphigus","volume":"389","author":"Schmidt","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2022060103033136000_B37","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1525-1470.2005.00118.x","article-title":"Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab)","volume":"22","author":"Kong","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"2022060103033136000_B38","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1111\/pde.12744","article-title":"Rituximab therapy for childhood pemphigus vulgaris","volume":"33","author":"Kincaid","year":"2016","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2022060103033136000_B39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.4103\/0378-6323.100587","article-title":"Childhood pemphigus vulgaris successfully treated with rituximab","volume":"78","author":"Kanwar","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"4","key":"2022060103033136000_B40","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2014.05.071","article-title":"Successful use of rituximab in the treatment of childhood and juvenile pemphigus","volume":"71","author":"Vinay","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2022060103033136000_B41","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0190-9622(88)70236-4","article-title":"Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults: a comparative study demonstrating clinical and immunopathologic overlap","volume":"19","author":"Wojnarowska","year":"1988","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2022060103033136000_B42","doi-asserted-by":"crossref","first-page":"F280","DOI":"10.1136\/adc.2003.037911","article-title":"Linear IgA bullous dermatosis in a neonate","volume":"89","author":"Lee","year":"2004","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"2","key":"2022060103033136000_B43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2230.1980.tb01684.x","article-title":"A study of benign chronic bullous dermatosis of childhood and comparison with dermatitis herpetiformis and bullous pemphigoid occurring in childhood","volume":"5","author":"Marsden","year":"1980","journal-title":"Clin Exp Dermatol"},{"issue":"7","key":"2022060103033136000_B44","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijporl.2004.02.014","article-title":"Upper aerodigestive tract complications in a neonate with linear IgA bullous dermatosis","volume":"68","author":"Gluth","year":"2004","journal-title":"Int J Pediatr Otorhinolaryngol"},{"issue":"3","key":"2022060103033136000_B45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5021\/ad.2015.27.3.315","article-title":"Concurrent drug-induced linear immunoglobulin A dermatosis and immunoglobulin A nephropathy","volume":"27","author":"Kim","year":"2015","journal-title":"Ann Dermatol"},{"issue":"5","key":"2022060103033136000_B46","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1046\/j.1365-2133.1999.03110.x","article-title":"Adult linear IgA disease and chronic bullous disease of childhood: the association with human lymphocyte antigens Cw7, B8, DR3 and tumour necrosis factor influences disease expression","volume":"141","author":"Collier","year":"1999","journal-title":"Br J Dermatol"},{"issue":"6","key":"2022060103033136000_B47","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1365-2133.1988.tb02593.x","article-title":"A comparative serological and molecular study of linear IgA disease and dermatitis herpetiformis","volume":"118","author":"Sachs","year":"1988","journal-title":"Br J Dermatol"},{"issue":"5","key":"2022060103033136000_B48","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1111\/j.1525-1470.2007.00438.x","article-title":"Childhood linear IgA bullous disease triggered by amoxicillin-clavulanic acid","volume":"24","author":"Ho","year":"2007","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"2022060103033136000_B49","first-page":"33","article-title":"Childhood linear IgA bullous disease induced by trimethoprim-sulfamethoxazole","volume":"3","author":"Nantel-Battista","year":"2010","journal-title":"J Dermatol Case Rep"},{"issue":"2","key":"2022060103033136000_B50","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.sder.2010.03.005","article-title":"Autoimmune blistering diseases in children","volume":"29","author":"Lara-Corrales","year":"2010","journal-title":"Semin Cutan Med Surg"},{"key":"2022060103033136000_B51","first-page":"97","article-title":"IgA-mediated autoimmune blistering diseases","volume-title":"Topics in Clinical Dermatology: Bullous Diseases","author":"McCord","year":"1993"},{"issue":"1","key":"2022060103033136000_B52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clindermatol.2011.03.008","article-title":"Linear immunoglobulin A bullous dermatosis","volume":"30","author":"Fortuna","year":"2012","journal-title":"Clin Dermatol"},{"key":"2022060103033136000_B53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/978-3-319-26728-9_12","article-title":"Autoimmune blistering diseases in children","volume-title":"Autoimmune Bullous Disease: Approach and Management","author":"Theos","year":"2016"},{"issue":"3","key":"2022060103033136000_B54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-4362.1997.00033.x","article-title":"Colchicine as a novel therapeutic agent in chronic bullous dermatosis of childhood","volume":"36","author":"Banodkar","year":"1997","journal-title":"Int J Dermatol"},{"issue":"4","key":"2022060103033136000_B55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/ajd.12795","article-title":"Colchicine in dermatology: a review","volume":"59","author":"Robinson","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"2","key":"2022060103033136000_B56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.det.2007.01.012","article-title":"Anti-inflammatory activity of tetracyclines","volume":"25","author":"Webster","year":"2007","journal-title":"Dermatol Clin"},{"issue":"4","key":"2022060103033136000_B57","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jaad.2005.11.1102","article-title":"Treatment of linear IgA bullous dermatosis of childhood with flucloxacillin","volume":"54","author":"Alajlan","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2022060103033136000_B58","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archderm.139.9.1121","article-title":"Treatment of linear IgA bullous dermatosis of childhood with mycophenolate mofetil","volume":"139","author":"Farley-Li","year":"2003","journal-title":"Arch Dermatol"},{"issue":"4","key":"2022060103033136000_B59","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1046\/j.0926-9959.2001.00269-9.x","article-title":"Response of chronic bullous dermatosis of childhood to a combination of dapsone and nicotinamide","volume":"15","author":"Khanna","year":"2001","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2022060103033136000_B60","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D31379S6T6","article-title":"Atypical response to treatment in linear IgA bullous dermatosis of childhood: revision of literature","volume":"17","author":"Moleiro","year":"2011","journal-title":"Dermatol Online J"},{"issue":"4","key":"2022060103033136000_B61","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1525-1470.1988.tb00896.x","article-title":"Chronic bullous dermatosis of childhood persisting into adulthood","volume":"5","author":"Burge","year":"1988","journal-title":"Pediatr Dermatol"},{"key":"2022060103033136000_B62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-3-319-26728-9_10","article-title":"Dermatitis herpetiformis","volume-title":"Autoimmune Bullous Disease: Approach and Management","author":"Patton","year":"2016"},{"issue":"5","key":"2022060103033136000_B63","first-page":"313","article-title":"Transglutaminases in skin epidermis","volume":"15","author":"Hitomi","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"3","key":"2022060103033136000_B64","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0016-5085(99)70482-8","article-title":"Tissue transglutaminase antibodies in dermatitis herpetiformis","volume":"117","author":"Porter","year":"1999","journal-title":"Gastroenterology"},{"issue":"12","key":"2022060103033136000_B65","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1001\/archderm.1992.04530010046006","article-title":"The incidence and prevalence of dermatitis herpetiformis in Utah","volume":"128","author":"Smith","year":"1992","journal-title":"Arch Dermatol"},{"issue":"4","key":"2022060103033136000_B66","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1525-1470.1997.tb00954.x","article-title":"Misdiagnosis, treatments, and outcomes in the immunobullous diseases in children","volume":"14","author":"Weston","year":"1997","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"2022060103033136000_B67","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ajg.2014.55","article-title":"Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study","volume":"109","author":"West","year":"2014","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"2022060103033136000_B68","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0738-081X(00)00184-X","article-title":"Dermatitis herpetiformis","volume":"19","author":"Reunala","year":"2001","journal-title":"Clin Dermatol"},{"issue":"6","key":"2022060103033136000_B69","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1468-3083.2009.03188.x","article-title":"Guidelines for the diagnosis and treatment of dermatitis herpetiformis","volume":"23","author":"Caproni","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2022060103033136000_B70","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1590\/abd1806-4841.20131775","article-title":"Review: dermatitis herpetiformis","volume":"88","author":"Mendes","year":"2013","journal-title":"An Bras Dermatol"},{"issue":"1","key":"2022060103033136000_B71","first-page":"4","article-title":"Gluten intolerance and skin diseases","volume":"16","author":"Humbert","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2022060103033136000_B72","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/bjd.13047","article-title":"Dermatitis herpetiformis in children: a long-term follow-up study","volume":"171","author":"Hervonen","year":"2014","journal-title":"Br J Dermatol"},{"issue":"6","key":"2022060103033136000_B73","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0190-9622(08)80657-3","article-title":"Efficacy of cyclosporine in two patients with dermatitis herpetiformis resistant to conventional therapy","volume":"28","author":"Stenveld","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"2022060103033136000_B74","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archderm.1980.01640360047016","article-title":"Treatment of dermatitis herpetiformis with colchicine","volume":"116","author":"Silvers","year":"1980","journal-title":"Arch Dermatol"},{"issue":"3","key":"2022060103033136000_B75","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0190-9622(08)81769-0","article-title":"Successful treatment of dermatitis herpetiformis with tetracycline and nicotinamide in a patient unable to tolerate dapsone","volume":"28","author":"Zemtsov","year":"1993","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2022060103033136000_B76","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jaad.2007.08.010","article-title":"Bullous pemphigoid in infancy: clinical and epidemiologic characteristics","volume":"58","author":"Waisbourd-Zinman","year":"2008","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2022060103033136000_B77","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00000372-200306000-00001","article-title":"Childhood bullous pemphigoid: a clinicopathologic study and review of the literature","volume":"25","author":"Fisler","year":"2003","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"2022060103033136000_B78","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1001\/archderm.136.4.527","article-title":"Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood","volume":"136","author":"Chimanovitch","year":"2000","journal-title":"Arch Dermatol"},{"issue":"2","key":"2022060103033136000_B79","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1468-3083.2008.02755.x","article-title":"Topical tacrolimus treatment for localized pretibial bullous phemphigoid","volume":"23","author":"Calcaterra","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2022060103033136000_B80","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s13023-014-0185-6","article-title":"Bullous pemphigoid in infants: characteristics, diagnosis and treatment","volume":"9","author":"Schwieger-Briel","year":"2014","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"2022060103033136000_B81","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/pde.12360","article-title":"Postvaccinal, corticosteroid-resistant bullous pemphigoid in infancy: treatment with intravenous immunoglobulin","volume":"31","author":"Ister","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"2022060103033136000_B82","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1346-8138.2007.00348.x","article-title":"Childhood bullous pemphigoid treated by i.v. immunoglobulin","volume":"34","author":"Xiao","year":"2007","journal-title":"J Dermatol"},{"issue":"2","key":"2022060103033136000_B83","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0190-9622(99)70481-0","article-title":"Childhood bullous pemphigoid: report of a case with characterization of the targeted antigens","volume":"40","author":"Trueb","year":"1999","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2022060103033136000_B84","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1365-2133.2006.07646.x","article-title":"Rituximab in autoimmune bullous diseases: mixed responses and adverse effects","volume":"156","author":"Schmidt","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"2022060103033136000_B85","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1111\/pde.12057","article-title":"Refractory childhood pemphigoid successfully treated with rituximab","volume":"30","author":"Fuertes","year":"2013","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"2022060103033136000_B86","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"2022060103033136000_B87","doi-asserted-by":"crossref","first-page":"85","DOI":"10.5021\/ad.1996.8.2.85","article-title":"Clinical features of epidermolysis bullosa acquisita","volume":"8","author":"Lee","year":"1996","journal-title":"Ann Dermatol (Seoul)"},{"key":"2022060103033136000_B88","doi-asserted-by":"crossref","first-page":"228e32","DOI":"10.1111\/1523-1747.ep12470317","article-title":"Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated","volume":"91","author":"Gammon","year":"1988","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2022060103033136000_B89","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1365-2133.2006.07443.x","article-title":"Childhood epidermolysis bullosa acquisita with autoantibodies against the noncollagenous 1 and 2 domains of type VII collagen: case report and review of the literature","volume":"155","author":"Mayuzumi","year":"2006","journal-title":"Br J Dermatol"},{"issue":"3","key":"2022060103033136000_B90","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archdermatol.2010.317","article-title":"Congenital epidermolysis bullosa acquisita: vertical transfer of maternal autoantibody from mother to infant","volume":"147","author":"Abrams","year":"2011","journal-title":"Arch Dermatol"},{"issue":"2","key":"2022060103033136000_B91","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2133.1967.tb11471.x","article-title":"Epidermolysis bullosa induced by penicillamine","volume":"79","author":"Beer","year":"1967","journal-title":"Br J Dermatol"},{"issue":"6024","key":"2022060103033136000_B92","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1136\/bmj.1.6024.1509","article-title":"Acquired epidermolysis bullosa due to high-dose frusemide","volume":"1","author":"Kennedy","year":"1976","journal-title":"BMJ"},{"issue":"3","key":"2022060103033136000_B93","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1046\/j.1525-1470.1998.1998015184.x","article-title":"Bullous pemphigoid and epidermolysis bullosa acquisita: presentation, prognosis, and immunopathology in 11 children","volume":"15","author":"Edwards","year":"1998","journal-title":"Pediatr Dermatol"},{"issue":"9","key":"2022060103033136000_B94","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/archderm.1997.03890450070008","article-title":"Epidermolysis bullosa acquisita in childhood","volume":"133","author":"Callot-Mellot","year":"1997","journal-title":"Arch Dermatol"},{"issue":"1","key":"2022060103033136000_B95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1440-0960.1998.tb01240.x","article-title":"Epidermolysis bullosa acquisita in childhood","volume":"39","author":"Su","year":"1998","journal-title":"Australas J Dermatol"},{"issue":"4","key":"2022060103033136000_B96","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jaad.2005.07.009","article-title":"Childhood IgA-mediated epidermolysis bullosa acquisita responding to mycophenolate mofetil as a corticosteroid-sparing agent","volume":"54","author":"Tran","year":"2006","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2022060103033136000_B97","doi-asserted-by":"crossref","first-page":"e979","DOI":"10.1111\/j.1365-2230.2009.03608.x","article-title":"Refractory epidermolysis bullosa acquisita: successful treatment with rituximab","volume":"34","author":"Saha","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2022060103033136000_B98","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/pde.12006","article-title":"A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy","volume":"31","author":"McKinley","year":"2014","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2022060103033136000_B99","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/1523-1747.ep12470317","article-title":"Increased frequency of HLA-DR2 in patients with autoantibodies to epidermolysis bullosa acquisita antigen: evidence that the expression of autoimmunity to type VII collagen is HLA class II allele associated","volume":"91","author":"Gammon","year":"1988","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2022060103033136000_B100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0046-8177(97)90281-1","article-title":"Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy","volume":"28","author":"Crowson","year":"1997","journal-title":"Hum Pathol"},{"issue":"7","key":"2022060103033136000_B101","doi-asserted-by":"crossref","first-page":"818","DOI":"10.3346\/jkms.2012.27.7.818","article-title":"Methimazole-induced bullous systemic lupus erythematosus: a case report","volume":"27","author":"Seo","year":"2012","journal-title":"J Korean Med Sci"},{"issue":"6","key":"2022060103033136000_B102","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.21873\/anticanres.13432","article-title":"Bullous lupus under nivolumab treatment for lung cancer: a case report with systematic literature review","volume":"39","author":"Wouters","year":"2019","journal-title":"Anticancer Res"},{"issue":"5","key":"2022060103033136000_B103","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/archderm.135.5.569","article-title":"Bullous systemic lupus erythematosus with autoantibodies recognizing multiple skin basement membrane components, bullous pemphigoid antigen 1, laminin-5, laminin-6, and type VII collagen","volume":"135","author":"Chan","year":"1999","journal-title":"Arch Dermatol"},{"issue":"1","key":"2022060103033136000_B104","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/pde.13015","article-title":"Case of pediatric bullous systemic lupus erythematosus treated with intravenous immunoglobulin","volume":"34","author":"Juh\u00e1sz","year":"2017","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"2022060103033136000_B105","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/RHU.0b013e318214f30c","article-title":"Rituximab in the treatment of bullous systemic lupus erythematosus","volume":"17","author":"Alsanafi","year":"2011","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"2022060103033136000_B106","first-page":"E5","article-title":"Bullous systemic lupus erythematosus successfully treated with rituximab","volume":"103","author":"Lowe","year":"2019","journal-title":"Cutis"},{"issue":"1","key":"2022060103033136000_B107","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1191\/0961203303lu241cr","article-title":"Bullous SLE: response to methotrexate and relationship with disease activity","volume":"12","author":"Malcangi","year":"2003","journal-title":"Lupus"},{"issue":"4","key":"2022060103033136000_B108","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1067\/mai.2000.109830","article-title":"Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma","volume":"106","author":"Covar","year":"2000","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"2022060103033136000_B109","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1089\/cap.2018.0017","article-title":"Steroid-induced psychosis in the pediatric population: a new case and review of the literature","volume":"28","author":"Hodgins","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"2","key":"2022060103033136000_B110","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jpeds.2011.01.017","article-title":"Risk factors for medication-induced diabetes and type 2 diabetes","volume":"159","author":"Amed","year":"2011","journal-title":"J Pediatr"},{"issue":"3","key":"2022060103033136000_B111","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"2","key":"2022060103033136000_B112","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaad.2016.02.1240","article-title":"Prevention and management of glucocorticoid-induced side effects: a comprehensive review: infectious complications and vaccination recommendations","volume":"76","author":"Caplan","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2022060103033136000_B113","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/bjd.18592","article-title":"The psychological functioning of children with epidermolysis bullosa and its relationship with specific aspects of disease","volume":"182","author":"Soon","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"2022060103033136000_B114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldu010","article-title":"Management of pain in advanced disease","volume":"110","author":"Harris","year":"2014","journal-title":"Br Med Bull"},{"issue":"1","key":"2022060103033136000_B115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/00004630-200101000-00003","article-title":"A retrospective study on the effectiveness of intranasal midazolam in pediatric burn patients","volume":"22","author":"Hansen","year":"2001","journal-title":"J Burn Care Rehabil"}],"container-title":["Pediatrics In Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article-pdf\/43\/6\/309\/1290335\/pedsinreview.2021005125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article-pdf\/43\/6\/309\/1290335\/pedsinreview.2021005125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T13:43:12Z","timestamp":1700660592000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatricsinreview\/article\/43\/6\/309\/188071\/Pediatric-Autoimmune-Bullous-Disease-A-Literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,1]]},"references-count":115,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/pir.2021-005125","relation":{},"ISSN":["0191-9601","1526-3347"],"issn-type":[{"type":"print","value":"0191-9601"},{"type":"electronic","value":"1526-3347"}],"subject":[],"published":{"date-parts":[[2022,6,1]]}}}